Wedbush has assumed coverage of Voyager Therapeutics (NASDAQ:VYGR) with an outperform rating, highlighting the company’s ...

Wedbush upgraded Voyager Therapeutics (VYGR) to Outperform from Neutral with a price target of $11, up from $7, after assuming coverage of the ...

Key Takeaways Wedbush upgraded Snowflake as the analysts predicted that the artificial intelligence software era is ...

Wedbush notes that in the past two weeks Kioxia filed for an IPO and SanDisk released its 10-12B, telling investors that data from these ...

Power needs for artificial intelligence and cloud computing are expanding so rapidly that some data center campuses may use ...

IMAX Corp.’s shares have climbed 71.2% in 2024, and analyst firm Wedbush sees more upside ahead for the high-end movie-theater operator.

The EV maker’s stock gained 3.7% on Friday, leaving the shares ahead nearly 40% for the year and giving it a market value of ...

Microsoft stock was lagging its tech peers on Friday as investors reacted to news the company is facing a broad inquiry from ...

A potential Trump administration may ease regulations for self-driving vehicles, accelerating Tesla's progress ...

On November 25, Wedbush upgraded the stock to Outperform from Neutral with a $135 price target. It is time for the broader software space to get in on the AI Party, the advisory told investors in ...

Apple Inc.’s skeptics and bears have missed the last more than $1 trillion upward move in the stock by overlooking three key dynamics behind the story, Wedbush analysts said Friday. Apple has an ...

Wedbush has assumed coverage of Voyager Therapeutics (NASDAQ:VYGR) with an outperform rating, highlighting the company’s TRACER platform. The investment firm said it believes TRACER alone should ...